Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])

Next Previous
Trial Profile

A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib
  • Indications Adenocarcinoma; Bladder cancer; Cholangiocarcinoma; Lung cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Skin cancer
  • Focus Adverse reactions
  • Sponsors Celgene Corporation

Most Recent Events

  • 13 Dec 2022 Results assessing assesses the safety of LEN-based treatment (including LEN+dexamethasone [Rd] and Rd+bortezomib [RVd]) or non-LEN treatment (including bortezomib+melphalan/prednisone [VMP]) in patients with TNE NDMM presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 27 May 2022 Planned End Date changed from 31 Mar 2025 to 13 Jan 2026.
  • 27 May 2022 Planned primary completion date changed from 31 Mar 2025 to 13 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top